Onconetix, Inc. (ONCO) Stock
ONCO Key Statistics
About Onconetix, Inc.
Onconetix, Inc., a biotechnology and pharmaceutical company, focuses on developing and commercializing transformational therapies to address health challenges worldwide. The company owns Entadfi, an FDA-approved, once daily pill that combines finasteride and tadalafil for the treatment of benign prostatic hyperplasia. It is also developing a streptococcus pneumoniae vaccine candidate, which is designed to prevent infectious middle ear infections in children, and prevention of pneumonia in the elderly; and universal flu vaccine that provide protection from all virulent strains in addition to licensing a novel norovirus S&P nanoparticle versatile virus-like particle vaccine platform from Cincinnati Children's to develop vaccines for multiple infectious diseases, including Marburg and monkeypox, and others. The company was formerly known as Blue Water Biotech, Inc. and changed its name to Onconetix, Inc. in December 2023. Onconetix, Inc. was incorporated in 2018 and is headquartered in Cincinnati, Ohio.
CEO: David Allan White. Company website
ONCO — Frequently Asked Questions
What is the ONCO stock price today?
Onconetix, Inc. (ONCO) trades at $3.58, down 48.49% on the day, as of Nov 12, 2026 10:46 UTC.
What is Onconetix, Inc.'s market cap?
Onconetix, Inc. has a market capitalisation of $12.27M, calculated from the live ONCO share price and shares outstanding.
What is the P/E ratio of ONCO?
ONCO has no meaningful price-to-earnings ratio: Onconetix, Inc. lost $516.96 per share over the last twelve months, and a P/E is only defined on positive earnings.
How much revenue does Onconetix, Inc. make?
Onconetix, Inc. generated revenue of $815,371.00 over the trailing twelve months, which puts the stock at 15.04 times sales.
What is the 52-week range for ONCO?
ONCO has traded between $0.12 and $14.20 over the past 52 weeks, and the last price is 74.8% below that high.
Is Onconetix, Inc. profitable?
No. Onconetix, Inc. is loss-making, with a net margin of -1,720.98% over the trailing twelve months.
What is the analyst price target for ONCO?
Wall Street analysts rate ONCO Buy.
What sector is Onconetix, Inc. in?
Onconetix, Inc. is classified under the Healthcare sector and the Biotechnology industry, and is domiciled in US .
Who is the CEO of Onconetix, Inc.?
David Allan White is the chief executive of Onconetix, Inc., which employs 12 people.
Where can I track ONCO in real time?
QFI Terminal shows ONCO with live charts, full financials, the options chain with gamma exposure, institutional ownership and analyst ratings on one screen. The free plan has no time limit and asks for no card.
See ONCO live in QFI Terminal
Interactive charts, full financials, options chain, gamma exposure, ownership and analyst ratings, all in one institutional-grade terminal.
Open ONCO in Terminal See plans